Live Update
From the Liveblog of
Tuesday, January 25, 2022
Pfizer, BioNTech begin Omicron vaccine trial
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies say in a statement.
The company’s head of vaccine research Kathrin Jansen says that while current data shows that boosters against the original COVID strain continue to protect against severe outcomes with Omicron, the company is acting out of caution.
If you’d like to comment, join
The Times of Israel Community.
The Times of Israel Community.
JOIN THE TOI COMMUNITY
Already a member? Log in here







